Invesco Ltd. Allakos Inc. Transaction History

Invesco Ltd.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.02 - $3.23 $1,161 - $3,678	-1,139 Reduced 3.59%	30,594 $38,000
Q4 2023 Feb 12, 2024	BUY	$1.72 - $3.18 $5,930 - $10,964	3,448 Added 12.19%	31,733 $86,000
Q3 2023 Nov 13, 2023	SELL	$2.13 - $5.55 $1,603 - $4,179	-753 Reduced 2.59%	28,285 $64,000
Q2 2023 Aug 11, 2023	BUY	$3.6 - $5.25 $104,536 - $152,449	29,038 New	29,038 $126,000
Q4 2022 Feb 13, 2023	SELL	$5.66 - $8.42 $742,903 - $1.11 Million	-131,255 Reduced 18.56%	575,931 $4.85 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $1.88 Million - $3.8 Million	620,953 Added 720.09%	707,186 $4.33 Million
Q2 2022 Aug 15, 2022	BUY	$2.6 - $6.14 $4,440 - $10,487	1,708 Added 2.02%	86,233 $270,000
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $336,743 - $650,285	66,288 Added 363.48%	84,525 $482,000
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $468,274 - $6.13 Million	-54,769 Reduced 75.02%	18,237 $179,000
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $1.25 Million - $1.8 Million	-16,335 Reduced 18.28%	73,006 $7.73 Million
Q2 2021 Aug 17, 2021	BUY	$85.37 - $114.1 $849,516 - $1.14 Million	9,951 Added 12.53%	89,341 $7.63 Million
Q1 2021 May 17, 2021	BUY	$109.73 - $153.66 $2.89 Million - $4.05 Million	26,369 Added 49.73%	79,390 $9.11 Million
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $4.22 Million - $8.08 Million	53,021 New	53,021 $7.42 Million
Q4 2019 Feb 14, 2020	SELL	$66.49 - $137.73 $3.58 Million - $7.42 Million	-53,853 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $1.67 Million - $4.83 Million	53,853 New	53,853 $4.23 Million

104

70.7M

43.8K

1.4K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $54.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.